Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVT23
- Development stage
- Unknown
- Lead developer
- Servatus Biopharmaceuticals
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
SVT23 is a live bacterial strain developed by the Australian biotechnology company Servatus Limited as a component of a topical live biotherapeutic product (LBP) for the treatment of atopic dermatitis. Formulated as a topical spray, SVT23 was designed to be administered twice daily in combination with two other bacterial strains, SVT9 and SVT26, to target dysbiosis and immune dysregulation in active atopic dermatitis lesions. A single-centre, open-label, single-arm exploratory Phase 0 clinical study in Australia (ACTRN12622001261718) was planned to evaluate this three-strain combination spray, but the trial was subsequently withdrawn. Specific details regarding the bacterial species of SVT23 and its precise biological targets remain undisclosed.
Beyond the preview
Go deeper on SVT23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVT23.